Beacon Capital Management LLC (Tennessee)’s CRISPR Therapeutics CRSP Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-268	Closed	-$13K	–	309
2025 Q2	$13K	Buy	268 +111	+71%	+$4.3K	﹤0.01%	580
2025 Q1	$5.34K	Buy	157 +89	+131%	+$3.77K	﹤0.01%	756
2024 Q4	$2.68K	Buy	+68	New	+$3.21K	﹤0.01%	831
2022 Q4	–	Sell	-50	Closed	-$3K	–	1002
2022 Q3	$3K	Hold	50	–	–	﹤0.01%	666
2022 Q2	$3K	Hold	50	–	–	﹤0.01%	707
2022 Q1	$3K	Buy	+50	New	+$3.14K	﹤0.01%	708

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s CRSP Position: Q3 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 268 shares — an estimated $13K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in CRSP in Q1 2022 and held it in 6 quarters. The position peaked at $13K in Q2 2025. 441 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Beacon Capital Management LLC (Tennessee) reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 268 CRISPR Therapeutics shares in Q3 2025, an estimated $13K.
Beacon Capital Management LLC (Tennessee) first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 6 quarters.
Beacon Capital Management LLC (Tennessee)'s CRISPR Therapeutics position peaked at $13K in Q2 2025.
441 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2025, filed 7 Nov 2025.